ARIAD Pharmaceuticals, Inc.
(NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.
Hugh Cole, senior vice president and chief business officer at ARIAD Pharmaceuticals (Photo: Business Wire)
Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Prior to joining ARIAD, he spent seven years at Shire Pharmaceuticals, most recently as senior vice president, strategic planning and program management and as a global franchise head, and before that, as vice president, business development. Previously, he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly Genome Therapeutics) and at Millennium Pharmaceuticals and its affiliates. Mr. Cole led numerous successful acquisitions both at Shire and Oscient.
“Hugh is a thoughtful and experienced executive who brings great value to our leadership team,” stated Dr. Berger. “He will be integral in seeking business and corporate development opportunities for ARIAD, including a commercial partnership for Iclusig
in Japan, as well as helping to further maximize our oncology pipeline.”
Hugh started his career as an investment analyst at Fred Alger Management and then as a Principal at the Wilkerson Group, a consulting and advisory firm. He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit
or follow ARIAD on Twitter (
This press release contains “forward-looking statements” including, but not limited to, statements about potential new business and corporate development opportunities and the ongoing development of our pipeline of cancer medicines. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to continued growth in market acceptance of Iclusig, risks and uncertainties associated with biotechnology drug development, the costs associated with our research, development, manufacturing and other activities, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.